Person:
BOZKURTLAR, EMİNE

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

BOZKURTLAR

First Name

EMİNE

Name

Filters

2016 - 201962020 - 20237
Reset filters

Settings

Start date: 2015 × Has files: true ×

Search Results

Now showing 1 - 10 of 13
  • Thumbnail Image
    PublicationOpen Access
    Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients— case series
    (2022-01-01) AKSOY, AYSUN; BOZKURTLAR, EMİNE; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; İNANÇ, GÜZİDE NEVSUN; KOCAKAYA, DERYA; AKSOY A., KOCAKAYA D., Yalçinkaya Y., BOZKURTLAR E., KARAKURT S., Eryüksel E., İnanç N.
    © TÜBİTAK.Background/aim: Rheumatoid pulmonary nodule can be detected in up to 32% of rheumatoid arthritis (RA) patients and approximately one-third of nodules may cavitate. We aimed to evaluate characteristics of patients with RA developing cavitary pulmonary nodular (CPN) lesions under disease-modifying antirheumatic drugs (DMARDs), follow-up of both cavitary and solid nodules, and their outcome with the treatment. Materials and methods: RA patients who presented with CPN lesions during follow-up were recruited retrospectively in this case series analysis. Total numbers and mean diameters of cavitary and solid nodules in each thorax computed tomography (CT) have been determined and followed up by two experienced pulmonary physicians. Moreover, changes in treatment after the development of the CPN lesions and characteristics of cavitary nodules were collected. Results: Eleven patients with CPN lesions were reported. At the time of CPN diagnosis, more patients were taking leflunomide than methotrexate (81% vs 19%). Half of the patients were receiving biologic therapy and only 18% were taking anti-TNF drugs. After a median of 24 (3–65) months of follow-up, the regression of CPN lesions was determined in 45% (5/11) of patients. Four of these 5 (80%) patients were switched to a treatment regimen without leflunomide and three of them to nonanti-TNF biologic treatment or targeted synthetic DMARDs (tocilizumab, tofacitinib, and rituximab). Conclusion: CPN lesions seen in RA patients are often pulmonary manifestations of the underlying disease; however, one must rule out malignancies or infections. If lesions progress under DMARDs, it is advised to discontinue synthetic DMARDs (LEF/MTX) and switch to another biological DMARD with different modes of action.
  • Thumbnail Image
    PublicationOpen Access
    Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?
    (ELSEVIER SCIENCE INC, 2019-10) BOZKURTLAR, EMİNE; Tuylu, T. Basoglu; Demircan, N. C.; Arikan, R.; Telli, T. Akin; Alan, O.; Ercelep, O.; Bozkurtlar, E.; Kocakaya, D.; Kaya, S.; Babacan, N.; Lacin, T.; Dane, F.; Ahiskali, R.; Batirel, H.; Yumuk, P. F.
  • Thumbnail Image
    PublicationOpen Access
    Optimal waiting period to surgical treatment after neoadjuvant chemoradiotherapy for locally advanced rectum cancer: A retrospective observational study
    (2023-12-01) ATICI, ALİ EMRE; BOZKURTLAR, EMİNE; YEGEN, ŞEVKET CUMHUR; Aslanov K., ATICI A. E., Karaman D., BOZKURTLAR E., YEGEN Ş. C.
    Background: The optimal waiting period after neoadjuvant treatment in patients with locally advanced rectal cancers is still controversial. The literature has different results regarding the effect of waiting periods on clinical and oncological outcomes. We aimed to investigate the effects of these different waiting periods on clinical, pathological, and oncological outcomes. Methods: Between January 2014 and December 2018, a total of 139 consecutive patients with locally advanced rectal adenocarcinoma, who were treated in the Department of General Surgery at the Marmara University Pendik Training and Research Hospital, were enrolled in the study. The patients were split into three groups according to waiting time for surgery after neoadjuvant treatment: group 1 (n = 51) included patients that have 7 weeks and less (≤ 7 weeks) time interval, group 2 (n = 45) 8 to 10 weeks (8–10 weeks), group 3 (n = 43) 11 weeks and above (11 weeks ≤). Their database records, which were entered prospectively, were analyzed retrospectively. Results: There were 83 (59.7%) males and 56 (40.3%) females. The median age was 60 years, and there was no statistical difference between the groups regarding age, gender, BMI, ASA score, ECOG performance score, tumor location, and preoperative CEA values. Also, we found no significant differences regarding operation times, intraoperative bleeding, length of hospital stay, and postoperative complications. According to the Clavien–Dindo (CD) classification, severe early postoperative complications (CD 3 and above) were observed in 9 patients. The complete pathological response (pCR, ypT0N0) was observed in 21 (15.1%) patients. The groups had no significant difference regarding 3-year disease-free and 3-year overall survival (p = 0.3, p = 0.8, respectively). Local recurrence was observed in 12 of 139 (8.6%) patients and distant metastases occurred in 30 of 139 (21.5%) patients during the follow-up period. There was no significant difference between the groups in terms of both local recurrence and distant metastasis (p = 0.98, p = 0.43, respectively). Conclusion: The optimal time for postoperative complications and sphincter-preserving surgery in patients with locally advanced rectal cancer is 8–10 weeks. The different waiting periods do not affect disease-free and overall survival. While long-term waiting time does not make a difference in pathological complete response rates, it negatively affects the TME quality rate.
  • Thumbnail Image
    PublicationOpen Access
    Unilocular and multilocular thymic cysts: A study on the possible histomorphological and/or clinical differences
    (2022-01-01) BOZKURTLAR, EMİNE; BOZKURTLAR E.
    Objective: Thymic cysts are rare mediastinal cystic pathologies and have two subtypes namely unilocular and multilocular. This study aims to investigate the clinicopathological characteristics of thymic cysts and to compare the clinical and histopathologic features of multilocular thymic cysts (MTCs) and unilocular thymic cysts (UTCs).
  • Thumbnail Image
    PublicationOpen Access
    Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study
    (2019-11-01) BOZKURTLAR, EMİNE; Shih A. R., Uruga H., BOZKURTLAR E., Chung J., Hariri L. P., Minami Y., Wang H., Yoshizawa A., Muzikansky A., Moreira A. L., et al.
    Aims The 2015 WHO classification for lung adenocarcinoma (ACA) provides criteria for adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (INV), but differentiating these entities can be difficult. As our understanding of prognostic significance increases, inconsistent classification is problematic. This study assesses agreement within an international panel of lung pathologists and identifies factors contributing to inconsistent classification. Methods and results Sixty slides of small lung ACAs were reviewed digitally by six lung pathologists in three rounds, with consensus conferences and examination of elastic stains in round 3. The panel independently reviewed each case to assess final diagnosis, invasive component size and predominant pattern. The kappa value for AIS and MIA versus INV decreased from 0.44 (round 1) to 0.30 and 0.34 (rounds 2 and 3). Interobserver agreement for invasion (AIS versus other) decreased from 0.34 (round 1) to 0.29 and 0.29 (rounds 2 and 3). The range of the measured invasive component in a single case was up to 19.2 mm among observers. Agreement was excellent in tumours with high-grade cytology and fair with low-grade cytology. Conclusions Interobserver agreement in small lung ACAs was fair to moderate, and improved minimally with elastic stains. Poor agreement is primarily attributable to subjectivity in pattern recognition, but high-grade cytology increases agreement. More reliable methods to differentiate histological patterns may be necessary, including refinement of the definitions as well as recognition of other features (such as high-grade cytology) as a formal part of routine assessment.
  • Thumbnail Image
    PublicationOpen Access
    Immunohistochemical expression of plasminogen activator inhibitor-1 in subcutaneous versus omental adipose tissue in patients after elective abdominal surgery
    (2019) BOZKURTLAR, EMİNE; Yildiz, Mehmet; Bozkurtlar, Emine; Azizy, Abdulmunir; Agirbasli, Mehmet
    Plasminogen activator inhibitor-1 (PAI-1) is a biomarker of thrombosis. Adipose and vascular tissues are among the major sources of PAI-1 production. Previous studies indicated that fat deposits mediate increased cardiovascular risk among obese individuals. We investigated the immunohistochemical (IHC) expression of PAI-1 in adipose and vascular tissues from the omentum and the subcutaneous tissue. The pathology samples were selected from 37 random patients who underwent elective abdominal surgery between 2008-2009. PAI-1 expression was semi-quantitatively scored and compared between the groups. Significant differences were noted in the IHC expression of PAI-1 between the omental and the subcutaneous adipose tissues (1.1 ± 0.8 versus 0.8 ± 0.6, respectively (p=0.05)). Adipose tissue displayed higher IHC expression of PAI-1 compared to vascular wall tissue in both omentum and subcutaneous sections (1.1 ± 0.8 versus 0.5 ± 0.9 (p=0.004), and 0.8 ± 0.6 versus 0.4 ± 0.6 (p=0.003), respectively). In conclusion, our study compared PAI-1 expression in the omentum versus the subcutaneous tissue and adipose versus vascular tissues. IHC expression of PAI-1 level was significantly higher in the omental adipose tissue compared to the subcutaneous adipose tissue. Adipose tissue displayed significantly higher PAI-1 expression than vascular tissue. The study elucidates the biological differences of adipose and vascular tissue from subcutaneous versus omental sections.
  • Thumbnail Image
    PublicationOpen Access
    Ebus: hasta başı değerlendi̇rmeni̇n önemi̇
    (2018-03-06) BOZKURTLAR, EMİNE; OLGUN YILDIZELİ, ŞEHNAZ; KOCAKAYA, DERYA; BOSTANCI, KORKUT; AHISKALI, ASİYE RENGİN; BOZKURTLAR E., ERÇETİN Y., OLGUN YILDIZELİ Ş., KOCAKAYA D., BOSTANCI K., AHISKALI A. R.
    Amaç: Endobronşial ultrasonografi (EBUS) aracılı biyopsi tüm dünyada yaygın olarak kullanılan ve hastaların morbidite sebebi olabilecek mediastinoskopi gibi işlemlerden kaçınmasını sağlayabilen kabul görmüş bir yöntemdir. Yapılan çalışmalarla duyarlılığı ve özgüllüğü kanıtlanmış bu yöntemin yakın zamanda merkezimizdeki uygulamalarda ortaya koyduğu sonuçları ve bunların klinikopatolojik yansımasını göstermeyi amaçlıyoruz. Gereç ve Yöntem: Mayıs 2016-Temmuz 2017 tarihleri arasında Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesi Patoloji Laboratuvarın’da değerlendirilen EBUS aracılı biyopsiler çalışmamıza alınmıştır. Olgulara ait klinik bilgiler retrospektif olarak merkezimiz sistemi üzerinden ve patolog eşliğinde işlem yapılan olgularda olgu patoloji formu üzerine patolog tarafından alınan notlardan elde edilmiştir. Bulgular: Toplam 61 olgunun değerlendirildiği çalışmamızda, 3 olguya 2 defa EBUS aracılı biyopsi uygulandığı görülmüştür. Bu olguların yalnız 5’inde hasta başı değerlendirme yapılmamıştır. Olgularda ortalama yaş 58, kadın/erkek oranı 20/41’dir. Olguların ön tanılarında sırasıyla malignite (%70, n=42), sarkoidoz (%30, n=18), enfeksiyon (tüberküloz dahil)(%16, n=10), lenfoma (%3, n=2) ve son olarak moleküler inceleme için yeni tümör dokusu (%2, n=1) yer almaktadır. Elli beş (%90) olguda mediastinal lenf noduna girilmiş, 4 (%7) olguda akciğerdeki kitleye, 2 (%3) mediastendeki kitleye ve 1 (%2) olguda hiler lenf noduna girilmiştir. Olgu başına yapılan ortalama girişim sayısı 4’tür. Dokuz olguda yetersiz sitolojik materyal değerlendirmesi yapılmıştır. Bu olguların 2’sinde hasta başı değerlendirme yapılamamış, 3 olguda 1’er girişim sonrası hasta uyumsuzluğu veya lezyon/lezyonların uygunsuzluğu nedeniyle işlem sonlandırılmak zorunda kalınmış, 4 olguda hasta başı değerlendirmede yetersiz ya da sınırlı sayıda hücre içeren materyal olduğu bildirilmiş kalıcı patolojik incelemede olgulara ait tüm materyal incelendiğinde tanı için yeterli materyalin olmadığı görülmüştür. Olguların kalıcı patoloji incelemesi/ hasta başı değerlendirme uyumuna bakacak olursak malignite pozitif olgularda %100 uyum (18/18) saptanırken, yetersiz olguları göz ardı edersek, malignite negatif olgularda da uyum %100 olarak saptanmaktadır. Granülom olarak raporlanan olgularda uyum %70 (10/7) olarak saptanmıştır. Malignite pozitif olgularımızdan 5’inde klinik istek üzerine hücre bloklarından moleküler inceleme yapılmış, bir olgudaki EGFR mutasyonu incelemesi açısından yetersizlik dışında, EGFR-ALK-ROS1 moleküler incelemelerinin tamamından sonuç alınabilmiştir. Sonuç EBUS aracılı biyopsi uygulamalarında klinik ön tanılarda sıkça yer alan malignite ve granülomatöz patolojiler çalışmamızda özellikle ele alınmıştır. Malignite pozitif olgularda hasta başı değerlendirme ve kalıcı patoloji incelemeleri uyumu %100 olarak saptanmıştır. Bu durum başta yeni tanı alan olgular olmak üzere klinik yönlendirmede hızlı ve doğru adımlar atılmasını sağlamaktadır. Ayrıca hasta başı değerlendirmenin “yetersiz” patoloji raporlarının sayısını azaltacağını düşündürmektedir. Aynı değerlendirme granülomatöz patolojiler açısından yapıldığında %70 olarak bulunmuştur. Bunun sebebinin büyük oranda işlem sırasındaki patoloji incelemesinde olguya ait tüm yayma lamlarının ve hücre bloğunun incelenememesinden kaynaklandığı görülmüştür.
  • Thumbnail Image
    PublicationOpen Access
    Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6
    (2023-01-01) BARIŞ, SAFA; YÜCELTEN, AYŞE DENİZ; BOZKURTLAR, EMİNE; CİNEL, ZELİHA LEYLA; AYDINER, ELİF; ÖZEN, AHMET OĞUZHAN; BARIŞ S., Benamar M., Chen Q., Catak M. C., Martínez-Blanco M., Wang M., Fong J., Massaad M. J., Sefer A. P., Kara A., et al.
    Background: Inborn errors of immunity have been implicated in causing immune dysregulation, including allergic diseases. STAT6 is a key regulator of allergic responses. Objectives: This study sought to characterize a novel gain-of-function STAT6 mutation identified in a child with severe allergic manifestations. Methods: Whole-exome and targeted gene sequencing, lymphocyte characterization, and molecular and functional analyses of mutated STAT6 were performed. Results: This study reports a child with a missense mutation in the DNA binding domain of STAT6 (c.1114G>A, p.E372K) who presented with severe atopic dermatitis, eosinophilia, and elevated IgE. Naive lymphocytes from the affected patient displayed increased TH2- and suppressed TH1- and TH17-cell responses. The mutation augmented both basal and cytokine-induced STAT6 phosphorylation without affecting dephosphorylation kinetics. Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reversed STAT6 hyperresponsiveness to IL-4, normalized TH1 and TH17 cells, suppressed the eosinophilia, and improved the patient\"s atopic dermatitis. Conclusions: This study identified a novel inborn error of immunity due to a STAT6 gain-of-function mutation that gave rise to severe allergic dysregulation. Janus kinase inhibitor therapy could represent an effective targeted treatment for this disorder.
  • Thumbnail Image
    PublicationOpen Access
    FDG PET/CT features of polysaccharide-based hemostatic agent chronic inflammatory changes can mimic metastatic lesions
    (2022-07-01) KOCAKAYA, DERYA; ASLAN, SEZER; BOZKURTLAR, EMİNE; Bozkurtlar E., Oksuzoglu K., Bostanci K., Aslan S., Kissa T. N., Kocakaya D., Ones T.
    Purpose To prevent hemorrhagic complications, hemostatic agents (HAs) have been widely used in recent years. The use of HAs can lead to false-positive results on postoperative imaging. There exists only 1 study in the literature evaluating these applications during surgical procedures. Therefore, we aimed to evaluate the postoperative imaging features of polysaccharide-based HAs in thoracic surgery patients who have had F-18-FDG PET/CT scans. Patients and Methods Two hundred nine consecutive patients who underwent thoracic surgery were enrolled in this study. A topical polysaccharide-based HA was applied to the surgical bed for all of the patients. The patients diagnosed with cancer were followed up with subsequent thoracic CT scans, and 42 of these patients were also imaged with F-18-FDG PET/CT, which then comprised the main study group. Due to suspicion of metastasis, 19/42 patients were reoperated or rebiopsied. The latest histopathological findings were accepted as criterion standard, and previous FDG PET/CT images were retrospectively reevaluated. Results Polysaccharide-based HAs that appear as amorphous basophilic material were identified in histopathological samples of 11/19 patients. Lymphocytes, plasma cells, and histiocytes, which formed foreign body reaction and/or foreign body granuloma, indicating the presence of chronic inflammation, were seen in all of the samples. F-18-FDG PET/CT showed increased FDG uptake in all of these lesions. Conclusions Despite the inconsistency of the literature, polysaccharide-based HAs can be demonstrated in human surgical specimens as amorphous basophilic materials even after a long time from the initial surgical procedure. These agents almost always cause chronic inflammatory changes. In addition, these agents may mimic \"false-positive\" findings on postoperative FDG PET/CT scans.
  • Thumbnail Image
    PublicationOpen Access
    Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma
    (2018-06) YILDIZELİ, BEDRETTİN; Batirel, Hasan Fevzi; Metintas, Muzaffer; Caglar, Hale Basak; Ak, Guntulu; Yumuk, Perran Fulden; Ahiskali, Rengin; Bozkurtlar, Emine; Bekiroglu, Nural; Lacin, Tunc; Yildizeli, Bedrettin; Yuksel, Mustafa